These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

201 related articles for article (PubMed ID: 17313422)

  • 41. [Update on the second line management of idiopathic overactive bladder].
    Chartier-Kastler E; Castro-Diaz D; De Ridder D; Everaert K; Sievert KD; Spinelli M; van Kerrebroeck P
    Prog Urol; 2009 Sep; 19(8):530-7. PubMed ID: 19699450
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Trigonal injection of botulinum toxin-A does not cause vesicoureteral reflux in neurogenic patients.
    Mascarenhas F; Cocuzza M; Gomes CM; Leão N
    Neurourol Urodyn; 2008; 27(4):311-4. PubMed ID: 17914742
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Comparing two types of botulinum-A toxin detrusor injections in patients with severe neurogenic detrusor overactivity: a case-control study.
    Grosse J; Kramer G; Jakse G
    BJU Int; 2009 Sep; 104(5):651-6. PubMed ID: 19281462
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Botulinum toxin treatment for anal fissure.
    Radwan MM; Ramdan K; Abu-Azab I; Abu-Zidan FM
    Afr Health Sci; 2007 Mar; 7(1):14-7. PubMed ID: 17604520
    [TBL] [Abstract][Full Text] [Related]  

  • 45. What treatment should we use if drugs fail for OAB; and, what really works after drugs?
    Bosch JL; Kelleher C; van Kerrebroeck PE; Schurch B
    Neurourol Urodyn; 2010 Apr; 29(4):658-61. PubMed ID: 20432331
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Botulinum toxin for cervical dystonia.
    Med Lett Drugs Ther; 2001 Jul; 43(1109):63-4. PubMed ID: 11468603
    [No Abstract]   [Full Text] [Related]  

  • 47. Severe post-herpetic neuralgia successfully treated with botulinum toxin A: three case reports.
    Sotiriou E; Apalla Z; Panagiotidou D; Ioannidis D
    Acta Derm Venereol; 2009; 89(2):214-5. PubMed ID: 19326024
    [No Abstract]   [Full Text] [Related]  

  • 48. Treatment of neuropathic bladder using botulinum toxin A in a 1-year-old child with myelomeningocele.
    Mall V; Glocker FX; Frankenschmidt A; Gordjani N; Heinen F; Brandis M; Korinthenberg R
    Pediatr Nephrol; 2001 Dec; 16(12):1161-2. PubMed ID: 11793122
    [No Abstract]   [Full Text] [Related]  

  • 49. Efficacy and complications of intradetrusor injection with botulinum toxin A in patients with refractory idiopathic detrusor overactivity.
    Jeffery S; Fynes M; Lee F; Wang K; Williams L; Morley R
    BJU Int; 2007 Dec; 100(6):1302-6. PubMed ID: 17979928
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Editorial comment.
    Blok BF
    Urology; 2010 Mar; 75(3):558. PubMed ID: 20211368
    [No Abstract]   [Full Text] [Related]  

  • 51. [Prospective study of the clinical and urodynamic results of intradetrusor botulinum toxin injections for the treatment of neurogenic overactive bladder].
    Bentaleb Y; Castel-Lacanal E; Sallusto F; De Boissezon X; Malavaud B; Marque P; Rischmann P; Gamé X
    Prog Urol; 2008 Jul; 18(7):449-55. PubMed ID: 18602606
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Botulinum neurotoxin A: an unusual systemic effect.
    Howell K; Selber P; Graham HK; Reddihough D
    J Paediatr Child Health; 2007 Jun; 43(6):499-501. PubMed ID: 17535186
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Editorial comment on: Six-year follow-up of botulinum toxin A intradetrusorial injections in patients with refractory neurogenic detrusor overactivity: clinical and urodynamic results.
    Fowler CJ
    Eur Urol; 2009 Mar; 55(3):712. PubMed ID: 18814958
    [No Abstract]   [Full Text] [Related]  

  • 54. Editorial comment on: Six-year follow-up of botulinum toxin A intradetrusorial injections in patients with refractory neurogenic detrusor overactivity: clinical and urodynamic results.
    Schurch B
    Eur Urol; 2009 Mar; 55(3):711-2. PubMed ID: 18814956
    [No Abstract]   [Full Text] [Related]  

  • 55. [Frontal muscular balance and botulinum toxin].
    Belhaouari L; Gassia V; Lauwers F
    Ann Chir Plast Esthet; 2004 Oct; 49(5):521-6. PubMed ID: 15518951
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Botulinum neurotoxin type A: the poison that can treat the sick.
    Novara G
    Eur Urol; 2009 Mar; 55(3):560-2. PubMed ID: 18805630
    [No Abstract]   [Full Text] [Related]  

  • 57. Editorial comment on: botulinum toxin A improves the quality of life of patients with neurogenic urinary incontinence.
    Kocjancic E
    Eur Urol; 2007 Sep; 52(3):858-9. PubMed ID: 17467880
    [No Abstract]   [Full Text] [Related]  

  • 58. Botulinum toxin: future developments.
    De Ridder D
    BJU Int; 2008 Jul; 102 Suppl 1():20-2. PubMed ID: 18665975
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Best practice in the use of onabotulinumtoxinA (BOTOX®) to optimize patient outcomes in overactive bladder.
    Chapple C
    Neurourol Urodyn; 2014 Jul; 33 Suppl 3():S1. PubMed ID: 25042136
    [No Abstract]   [Full Text] [Related]  

  • 60. [Patient follow-up after botulinum toxin intradetrusor injection. Proposal for management in neurogenic patients].
    de Sèze M; Ruffion A; Haab F; Chartier-Kastler E; Denys P; Game X; Karsenty G; Kerdraon J; Perrouin-Verbe B; Saussine C; Soler JM; Amarenco G
    Ann Readapt Med Phys; 2008 May; 51(4):315-21. PubMed ID: 18514963
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.